November 6, 2017, New York–Ludwig Cancer Research has released the scope of its participation at the 2017 Society for Immunotherapy of Cancer (SITC) Annual Meeting in National Harbor, Maryland, November 8-12.
Ludwig scientists will share data at the conference from preclinical and clinical studies of new immunotherapeutic strategies. These include updates on overall survival from the combination of anti-CTLA-4 and anti-PD-1 checkpoint blockade immunotherapies for advanced melanoma. Ludwig researchers will also present a phase 1 clinical trial combining a PI3K-gamma inhibitor alone and in combination with PD-1 blockade in patients with advanced solid tumors, and a novel immunotherapeutic approach to boosting the anti-cancer efficacy of radiotherapy.
Other presentations focus on the tumor microenvironment, including metabolic approaches to re-educating suppressive immune cells and the three-dimensional mapping of the immune landscape within tumors. A variety of other studies presented by Ludwig researchers will cover new findings on how tumors suppress immune responses, and the immune mechanisms underlying the anti-tumor effects and complex toxicities of immunotherapy.
Click here for a comprehensive list of Ludwig scientists’ activities at the meeting.
About Ludwig Cancer Research
Ludwig Cancer Research is an international collaborative network of acclaimed scientists that has pioneered cancer research and landmark discovery for more than 40 years. Ludwig combines basic science with the ability to translate its discoveries and conduct clinical trials to accelerate the development of new cancer diagnostics and therapies. Since 1971, Ludwig has invested $2.7 billion in life-changing science through the not-for-profit Ludwig Institute for Cancer Research and the six U.S.-based Ludwig Centers. To learn more, visit www.ludwigcancerresearch.org.
For further information please contact Rachel Reinhardt, rreinhardt@licr.org or +1-212-450-1582.